The results from the open label phase 2 trial confirm that Rebiotix’s drug, RBX2660, is the frontrunner among a coming wave of new microbiome treatments. The Minnesota-based company is focused ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

While CDI can be resolved with antibiotics, the drugs are often ineffective against dormant spore forms of C. diff, which can germinate and grow after the course is completed. CDI causes nearly ...

Acurx Pharmaceuticals (NASDAQ:ACXP) stock plunged 26% in midday trading amid the release of data from a Phase 2b clinical trial for its C. diff treatment ibezapolstat. The biotech company said the ...